![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://ir.ardelyx.com/news-releases/news-release-details/fda-approves-xphozahr-tenapanor-first-class-phosphate-absorption
https://www.globenewswire.com/news-release/2024/07/17/2914952/0/en/Ardelyx-AAKP-and-NMQF-File-Lawsuit-to-Protect-Dialysis-Patient-Choice-and-Timely-Access-to-Clinically-Meaningful-Medicines.html
https://www.globenewswire.com/news-release/2024/07/02/2907293/0/en/To-Preserve-Patient-Access-to-XPHOZAH-Ardelyx-Chooses-Not-to-File-for-TDAPA.html
https://www.globenewswire.com/news-release/2024/06/28/2905822/0/en/Ardelyx-Presents-Additional-Data-Detailing-Educational-Needs-Related-to-IBS-C-Management-Across-Healthcare-Disciplines.html
https://www.globenewswire.com/news-release/2024/05/30/2891114/0/en/Ardelyx-Inc-Reports-Employment-Inducement-Grants.html
https://www.globenewswire.com/news-release/2024/05/22/2886462/0/en/Ardelyx-to-Participate-at-the-2024-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/21/2885550/0/en/Ardelyx-Presents-Additional-Data-at-the-2024-Digestive-Disease-Week-Conference-on-IBSRELA-tenapanor-a-First-In-Class-Treatment-for-IBS-C-in-Adults.html
https://www.globenewswire.com/news-release/2024/05/16/2883372/0/en/Ardelyx-Presents-Additional-Data-at-the-NKF-2024-Spring-Clinical-Meetings-on-XPHOZAH-tenapanor.html
https://www.globenewswire.com/news-release/2024/05/14/2881843/0/en/Ardelyx-Inc-Reports-Employment-Inducement-Grants.html
https://www.globenewswire.com/news-release/2024/05/07/2876706/0/en/Ardelyx-to-Present-Additional-Data-Supporting-First-In-Class-IBSRELA-tenapanor-for-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-at-the-2024-Digestive-Disease-Week-Confere.html